epigallocatechin gallate has been researched along with Cognition Disorders in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Funayama, S; Izuo, N; Kim, J; Shimizu, T | 1 |
| Fan, J; Nan, S; Wang, P; Zhang, Y | 1 |
| Hong, H; Li, Y; Su, B | 1 |
| Cortés, MJ; Cuenca-Royo, A; de la Torre, R; de Sola, S; Del Hoyo, L; Dierssen, M; Espadaler, JM; Esteba, S; Farré, M; Gomis-González, M; Hernandez, G; Langohr, K; León, A; Martínez-Leal, R; Milá, M; Novell, R; Ozaita, A; Rodriguez, J; Sánchez-Gutiérrez, J; Xicota, L | 1 |
| Chang, X; Chen, Y; Cheng, S; Dun, W; Fang, S; Gu, X; He, W; Hou, X; Hu, Q; Liu, S; Mo, Y; Rong, C; Su, R; Wang, Q; Yang, C; Zhang, C; Zhang, L | 1 |
| Abeysekera, I; Dria, KJ; Goodlett, CR; Roper, RJ; Stringer, M | 1 |
| Cho, WJ; Han, JY; Jung, YD; Kim, JH; Kim, JK; Lee, SG; Oh, BS | 1 |
| Benejam, B; Blanco-Hinojo, L; Bléhaut, H; Catuara-Solarz, S; Cuenca-Royo, A; de la Torre, R; de Sola, S; Del Hoyo, L; Delabar, JM; Dierssen, M; Dueñas-Espín, I; Espadaler, JM; Farré, M; Fitó, M; Hernandez, G; Janel, N; Langohr, K; Principe, A; Pujol, J; Rodriguez, J; Sanchez-Benavides, G; Videla, S; Xicota, L | 1 |
| Kim, J; Lee, HJ; Lee, KW | 1 |
| Chopra, K; Kuhad, A; Tiwari, V | 1 |
| Abraham, NG; Calogero, C; Caruso, C; Fabio, G; Nader, AG; Scapagnini, G; Sonya, V; Vasto, S; Zella, D | 1 |
| Hashimoto, S; Imano, M; Ito, A; Itoh, T; Nishida, S; Satou, T; Tsubaki, M | 1 |
| Gomez-Pinilla, F; Nguyen, TT | 1 |
| Arendash, GW; Fernandez, F; Hou, H; Jensen, M; Rezai-Zadeh, K; Runfeldt, M; Shytle, RD; Tan, J | 1 |
3 review(s) available for epigallocatechin gallate and Cognition Disorders
| Article | Year |
|---|---|
Naturally occurring phytochemicals for the prevention of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Catechin; Cognition Disorders; Curcumin; Dietary Supplements; Humans; Oxidative Stress; Phytotherapy; Plant Extracts; Resveratrol; Stilbenes | 2010 |
Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders.
Topics: Animals; Antioxidants; Catechin; Cognition Disorders; Curcumin; Diet; Food; Heme Oxygenase-1; Humans; Molecular Structure; Neurodegenerative Diseases; Neuroprotective Agents; NF-E2-Related Factor 2; Polyphenols; Response Elements | 2011 |
Natural mood foods: the actions of polyphenols against psychiatric and cognitive disorders.
Topics: Affect; Animals; Antioxidants; Brain; Catechin; Cognition Disorders; Curcumin; Diet; Energy Intake; Energy Metabolism; Food Preferences; Humans; Nervous System Physiological Phenomena; Neurodegenerative Diseases; Oxidative Stress; Polyphenols | 2012 |
2 trial(s) available for epigallocatechin gallate and Cognition Disorders
| Article | Year |
|---|---|
A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.
Topics: Adult; Animals; Catechin; Cognition Disorders; Disease Models, Animal; Double-Blind Method; Female; Fragile X Syndrome; Humans; Male; Mice; Mice, Knockout; Middle Aged; Neuroprotective Agents; Treatment Outcome; Young Adult | 2020 |
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
Topics: Adaptation, Psychological; Adult; Catechin; Cholesterol; Cognition Disorders; Cognitive Behavioral Therapy; Double-Blind Method; Down Syndrome; Female; Follow-Up Studies; Homocysteine; Humans; Inhibition, Psychological; Male; Neuroprotective Agents; Recognition, Psychology; Retrospective Studies; Spain; Treatment Outcome; Young Adult | 2016 |
9 other study(ies) available for epigallocatechin gallate and Cognition Disorders
| Article | Year |
|---|---|
Dietary supplementation of a high-temperature-processed green tea extract attenuates cognitive impairment in PS2 and Tg2576 mice.
Topics: Amyloid beta-Peptides; Animals; Camellia sinensis; Catechin; Cognition Disorders; Dietary Supplements; Hot Temperature; Mice; Mice, Transgenic; PC12 Cells; Plant Extracts; Presenilin-2; Rats | 2019 |
Epigallocatechin-3-Gallate Provides Protection Against Alzheimer's Disease-Induced Learning and Memory Impairments in Rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Antioxidants; Aspartic Acid Endopeptidases; Catechin; Cognition Disorders; Dose-Response Relationship, Drug; Hippocampus; Male; Maze Learning; Memory Disorders; Neuroprotective Agents; Peptide Fragments; Rats; Rats, Sprague-Dawley; Spatial Memory; tau Proteins | 2021 |
Identification of Circulating miR-125b as a Potential Biomarker of Alzheimer's Disease in APP/PS1 Transgenic Mouse.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Biomarkers; Catechin; Cell Line, Tumor; Cognition Disorders; Disease Models, Animal; Gene Expression Regulation; Humans; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; MicroRNAs; Mutation; Neuroblastoma; Presenilin-1; Protease Inhibitors; RNA, Messenger | 2017 |
(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.
Topics: Alzheimer Disease; Animals; Catechin; Cell Proliferation; Cells, Cultured; CHO Cells; Cognition Disorders; Cricetulus; Disease Models, Animal; Mice; Neprilysin; Stereoisomerism; Up-Regulation | 2015 |
Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
Topics: Aging; Animals; Behavior, Animal; Brain Chemistry; Catechin; Cognition Disorders; Down Syndrome; Dyrk Kinases; Female; Growth; Learning; Maze Learning; Mice; Mice, Transgenic; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Recognition, Psychology | 2015 |
Neurorestorative effects of epigallocatechin-3-Gallate on cognitive function in a chronic cerebral hypoperfusion rat model.
Topics: Animals; Brain-Derived Neurotrophic Factor; Catechin; Cerebrovascular Disorders; Cognition Disorders; Disease Models, Animal; Drug Administration Routes; Escape Reaction; Hippocampus; Male; Malondialdehyde; Maze Learning; Neuroprotective Agents; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Superoxide Dismutase; Vascular Endothelial Growth Factor A | 2016 |
Epigallocatechin-3-gallate ameliorates alcohol-induced cognitive dysfunctions and apoptotic neurodegeneration in the developing rat brain.
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Catechin; Cognition Disorders; Ethanol; Male; Maze Learning; Neurodegenerative Diseases; Random Allocation; Rats; Rats, Wistar | 2010 |
(-)-Epigallocatechin-3-gallate protects against neuronal cell death and improves cerebral function after traumatic brain injury in rats.
Topics: Animals; Apoptosis; Brain Injuries; Catechin; Cerebral Cortex; Cognition Disorders; DNA, Single-Stranded; Lipid Peroxidation; Male; Malondialdehyde; Neurons; Neuroprotective Agents; Rats; Rats, Wistar; Tea | 2011 |
Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Catechin; Cognition Disorders; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Maze Learning; Mice; Mice, Transgenic; Mutation; Neuroprotective Agents; Phosphorylation; tau Proteins | 2008 |